

OFFICIALLY LICENSED
BEST OF ASCO[®]
ASCO21 Virtual



THE 16th BEST OF ASCO21 VIRTUAL

July 08 - 10, 2021

Organized by AUBMC

Licensed by ASCO

In collaboration with AMAAC and LSMO

www.bestofasco.org

PLANNING COMMITTEE:

Nagi S. El Saghir, MD (Chair) - Nizar Bitar, MD (Co-chair) - Sami Khatib (Co-chair)

SCIENTIFIC COMMITTEE:

Hikmat Abdel-Razeq, MD - Sana Al-Sukhun, MD - Tahseen Al-Rubaii, MD - Hazem Assi, MD - Ali Bazarbachi, MD - Nizar Bitar, MD - Adda Bounedjar, MD
Georges Chahine, MD Jean El-Cheikh, MD - Nagi El Saghir, MD (Chair) - Fadi Farhat, MD, MHHM - Hady Ghanem, MD - Khaled Ibrahim, MD Marwan Ghosn, MD
Ahmad Ibrahim, MD - Joseph Kattan, MD - Joseph Makdessi, MD - Fadi Nasr, MD - Ghazi Nsouli, MD - Arafat Tfayli, MD - Roger Khater, MD - Therese Abou Nasr, MD
Rita Murr, MD - Hanane Yassine, MD - Walid Moukkadem, MD

GUEST FACULTY:

Hikmat Abdel-Razeq, MD | Amman, JO - Ghassan Abou-Alfa, MD | New York, NY, USA - Sana Al-Sukhun, MD | Amman, JO - Ahmad Awada, MD | Brussels, BE
David Cameron, MD | Edinburgh, UK - Toni K. Choueiri, MD | Boston, MA, USA - Shaheena Dawood, MD | Dubai, UAE - Hesham El-Ghazali, MD | Cairo, Egypt
Zahera Fahed, MD | Damascus, Syria - Hassan Ghazal, MD - Hassan Jaafar, MD - Nuhad Ibrahim, MD | Houston, TX, USA - Sami Khatib, MD | AMAAC
Maroun Khoury, MD - Fadlo Khuri, MD | Beirut, Lebanon - Maha Manachi, MD - Mohamad Mohty, MD | Paris, FR - Eileen O'Reilly, MD | New York, NY, USA
Philip Philip, MD | Detroit, MI, USA - Mark Robson, MD | New York, NY, USA - Hussein Tawbi, MD, PhD | Houston, TX, USA - Adda Bounedjar, MD - Hassan Ghazal, MD
Hussein Sadek, MD

LEBANON FACULTY:

Dany Abi Gerges, MD - Iman Abou Dalle, MD - Hazem Assi, MD - Rita Assi, MD - Ali Bazarbachi, MD - Nizar Bitar, MD - Georges Chahine, MD - Jean El-Cheikh, MD
Nagi El Saghir, MD - Fadi Farhat, MD, MHHM - Hady Ghanem, MD - Khaled Ibrahim, MD - Marwan Ghosn, MD - Ahmad Ibrahim, MD - Joseph Kattan, MD - Roger Khater, MD
Fadlo Khuri, MD - Hampig Kourie, MD - Joseph Makdessi, MD - Walid Moukaddem, MD - Deborah Mukherji, MD - Fadi Nasr, MD - Muhieddine Seoud, MD - Sally Temraz, MD
Arafat Tfayli, MD - Roula Farah, MD, FAAP - Therese Abi Nasr, MD - Salim Chammas, MD - Nabil Chamseddine, MD - Fares Azouri, MD - Adnan Attalah, MD
Mohamad Yassine, MD - Roger Moukarbel, MD - Zeina Ayoub, MD - Pierre Sfeir, MD - Bassem Youssef, MD - Ali Shamseddine, MD - Mona Ayoubi, MD - Ghazi Nsouli, MD
Reem Abdallah, MD - David Attalah, MD - Miguel Abboud, MD - Raya Saab, MD - Haifa Dbouk, MD - Marcel Massoud, MD - Mohamad Bulbul, MD - Albert Hajj, MD - Toufic Eid, MD
Antoine Finianos, MD - Samar Mouwakkit, MD - Hiba Moukaddem, MD - Zeina Ayoub, MD

Thursday, July 8th, 2021

10:00 - 10:15 Opening Welcome Notes:
Nagi S. El Saghir, MD, AUBMC, Best of ASCO21 Lebanon
Nizar Bitar, MD, President LSMO, Co-Chair, Best of ASCO21 Lebanon
Sami Khatib, MD, President, Co-Chair, Best of ASCO21 Lebanon

Hematological Malignancies Sessions:

10:15 - 10:45 Hematologic Malignancies - Leukemia, MDS, and Allogeneic Transplant

Chairpersons: Nizar Bitar, MD - Sami Khatib, MD

Speakers: Iman Abou Dalle, MD - Mohamad Mohty, MD

10:15 - 10:25 OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).
[Abstract 7000, Jorge E. Cortes, MD](#) | Presented by [Iman Abou Dalle, MD](#)

10:25 - 10:35 The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).
[Abstract 7003, Taiga Nishihori, MD](#) | Presented by [Mohamad Mohty, MD](#)

10:35 - 10:45 Q & A

Thursday, July 8th, 2021

10:45 - 11:35 Hematologic Malignancies - Lymphoma and CLL

Chairpersons: Adnan Atallah, MD - Hanane Yassine, MD

Speakers: Rita Assi, MD - Ali Bazarbachi, MD - Mohamad Mohty, MD

- 10:45 - 10:55 First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
[Abstract 7500](#), John C. Byrd, MD | Presented by Rita Assi, MD
- 10:55 - 11:05 Myeloablative vs non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma CALGB 51101 (Alliance). [Abstract 7506](#), Tracy Batchelor, MD | Presented by Ali Bazarbachi, MD
- 11:05 - 11:15 Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE.
[Abstract 8005](#), Saad Zafar Usmani, FACP, MBA, MD | Presented by Mohamad Mohty, MD
- 11:15 - 11:25 Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
[Abstract 8008](#), Jesus G. Berdeja, MD | Presented by Mohamad Mohty, MD
- 11:25 - 11:35 Q & A

11:35 - 12:05 Non-CME non-Best of ASCO Satellite Symposium by Abbvie

Think Deep...Reach Deep with Venclexta in CLL | Nizar Bitar, MD

Thursday, July 8th, 2021

12:05 - 12:35 Non-CME non-Best of ASCO Satellite Symposium by Amgen
Updates in the Management of Relapsed Multiple Myeloma | [Nabil Chamseddine, MD](#)

12:35 - 12:45 Break

12:45 - 13:25 **Head and Neck Cancer, Lung Cancer Sessions**
Chairperson: Roger Moukarbel, MD
Speakers: Fadlo Khuri, MD - Fadi Farhat, MD, MHHM

12:45 - 12:55 **Plenary Session Abstract:** JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
[LBA2, Rui-hua Xu, MD, PhD](#) | [Presented by Fadlo Khuri, MD](#)

12:55 - 13:05 Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase III trial.
[Abstract 6000, Li Zhang, MD](#) | [Presented by Fadlo Khuri, MD](#)

13:05 - 13:15 Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial.
[Abstract 6001, Marcia S. Brose, MD, PhD, FASCO](#) | [Presented by Fadi Farhat, MD, MHHM](#)

13:15 - 13:25 Q & A

Thursday, July 8th, 2021

13:25 - 14:05 Lung Cancer - Non-Small Cell Local-Regional / Small Cell / Other

Chairpersons: Salim Chammas, MD - Ghazi Nsouli, MD

Speakers: Arafat Tfayli, MD - Pierre Sfeir, MD - Bassem Youssef, MD

13:25 - 13:35 IMpower010: Primary results of a phase III global study of atezolizumab vs. best supportive care after adjuvant chemotherapy in resected Stage IB-IIIa non-small cell lung cancer (NSCLC).

[Abstract 8500](#), Heather A. Wakelee, FASCO, MD | Presented by Arafat Tfayli, MD

13:35 - 13:45 Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: One-year results from a randomized controlled trial (VIOLET).

[Abstract 8504](#), Eric Kian Saik Lim, MD, MBBS | Presented by Pierre Sfeir, MD

13:45 - 13:55 Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.

[Abstract 8505](#), Jeffrey A Bogart, MD | Presented by Bassem Youssef, MD

13:55 - 14:05 Q & A

14:05 - 14:35 Non-CME non-Best of ASCO Satellite Symposium by Pfizer

Meet ALK+ NSCLC Heads On with Lorbreña | [Nizar Bitar, MD](#)

Thursday, July 8th, 2021

14:35 - 15:15 Lung Cancer - Non-Small Cell Metastatic

Chairpersons: Fares Azouri, MD - Adda Bou Nedjar, MD

Speakers: Fadlo Khuri, MD - Joseph Makdessi, MD - Hazem Assi, MD

14:35 - 14:45 Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.
[Abstract 9002](#), Mark A. Socinski, MD | Presented by [Fadlo Khuri, MD](#)

14:45 - 14:55 First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
[Abstract 9000](#), Martin Reck, MD, PhD | Presented by [Joseph Madessi, MD](#)

14:55 - 15:05 Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
[Abstract 9006](#), Joshua Bauml, MD | Presented by [Hazem Assi, MD](#)

15:05 - 15:15 Q & A

15:15 - 15:45 Non-CME non-Best of ASCO Satellite Symposium by MSD
Pembrolizumab, Redefining Survival Expectations in Frontline mNSCLC | [Marwan Ghosn, MD](#)

15:45 - 15:55 Break

Thursday, July 8th, 2021

15:55 - 16:45 **Gastrointestinal Cancer - Colorectal and Anal**

Chairpersons: Dany Abi Gergis, MD - Therese Abi Nasr, MD

Speakers: Eileen O'Reilly, MD - Ali Shamseddine, MD - Sally Temraz, MD

- 15:55 - 16:05 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.
[Abstract 3500](#), Thierry Andre, MD | Presented by Eileen O'Reilly, MD
- 16:05 - 16:15 Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.
[Abstract 3504](#), Richard Adams, FRCP, MRCP, MD, MBBS | Presented by Ali Shamseddine, MD
- 16:15 - 16:25 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
[Abstract 3505](#), Takayuki Yoshino, MD, PhD | Presented by Eileen O'Reilly, MD
- 16:25 - 16:35 The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.
[Abstract 3507](#), Yasutoshi Kuboki, PhD, MD | Presented by Sally Temraz, MD
- 16:35 - 16:45 Q & A

Thursday, July 8th, 2021

16:45 - 17:35 **Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary**

Chairpersons: Maha Manachi, MD - Walid Moukaddem, MD

Speakers: Ghassan Abou Alfa, MD - Philip A. Philip, MD

- 16:45 - 16:55 Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).
[Abstract 4006, Changhoon Yoo, MD, PhD](#) | Presented by Ghassan Abou Alfa, MD
- 16:55 - 17:05 Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577.
[Abstract 4003, Ronan Joseph Kelly, MBA, MD](#) | Presented by Philip Philip, MD
- 17:05 - 17:15 Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
[Abstract LBA4001, Ian Chau, MD](#) | Presented by Philip Philip, MD
- 17:15 - 17:25 Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study).
[Abstract 4007, Ning Lyu, MD](#) | Presented by Ghassan Abou Alfa, MD
- 17:25 - 17:35 Q & A

Thursday, July 8th, 2021

17:35 - 18:25 Melanoma / Skin Cancers and Sarcoma and Developmental Therapeutics - Immunotherapy Sessions

Chairperson: Georges Chahine, MD

Speakers: Hussein Tawbi, MD, PhD - Ahmad Awada, MD

- 17:35 - 17:45 Relatlimab (RELA) + nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase 3 results from RELATIVITY-047 (CA224-047).
[Abstract 9503](#), Evan J. Lipson, MD | Presented by Hussein Tawbi, MD, PhD
- 17:45 - 17:55 Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
[Abstract 9500](#), Alexander M. Eggermont, MD, PhD, FASCO, BA | Presented by Hussein Tawbi, MD, PhD
- 17:55 - 18:05 CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
[Abstract 9506](#), Jedd D. Wolchok, MD, PhD, FASCO | Presented by Hussein Tawbi, MD, PhD
- 18:05 - 18:15 Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.
[Abstract 9502](#), Rodabe Navroze Amaria, MD | Presented by Ahmad Awada, MD
- 18:15 - 18:25 Q & A

Friday, July 9th, 2021

11:00 - 11:50 Hematologic Malignancies - Plasma Cell Dyscrasia

Chairpersons: Nizar Bitar, MD - Fadi Nasr, MD

Speakers: Jean El Cheikh, MD - Khaled Ibrahim, MD - Ali Bazarbachi, MD - Ahmad Ibrahim, MD

- 11:00 - 11:10 CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).
[Abstract 7507](#), Ann S. LaCasce, MD | Presented by Jean El Cheikh, MD
- 11:10 - 11:20 ECOG-ACRIN E1411 Randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab +/- lenalidomide consolidation for Mantle Cell. [Abstract 7503](#), Mitchell Reed Smith, MD, PhD | Presented by Khaled Ibrahim, MD
- 11:20 - 11:30 Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. [Abstract 8004](#), Philippe Moreau, MD | Presented by Ali Bazarbachi, MD
- 11:30 - 11:40 Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).
[Abstract 8000](#), Kwee Yong, MBBS, PhD, FRCP, FRCPath | Presented by Ahmad Ibrahim, MD
- 11:40 - 11:50 Q & A

Friday, July 9th, 2021

11:50 - 12:20 Non-CME non-Best of ASCO Satellite Symposium by Takeda
Adcetris On The Front-Line Managing Patients with CD30+ HL | [Iman Abou Dalle, MD](#)

12:20 - 12:50 Central Nervous System Tumors Sessions
Chairpersons: Georges Hachem, MD
Speakers: Hassan Ghazal MD - Hazem Assi MD

12:20 - 12:30 Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.
[Abstract 2000, Priscilla Kaliopi Brastianos, MD](#) | [Presented by Hassan Ghazal, MD](#)

12:30 - 12:40 Long-term results of the GEINO 140 TRIAL: randomizing patients to stop or to continue temozolomide until 12 cycles.
[Abstract 2013, Marta Domenech](#) | [Presented by Hazem Assi, MD](#)

12:40 - 12:50 Q & A

Friday, July 9th, 2021

12:50 - 13:20 Care Delivery and Regulatory Policy

Chairperson: Nagi El Saghir, MD

Speakers: Ghazi Nsouli, MD - Hady Ghanem, MD

12:50 - 13:00 Outcomes of COVID-19 in cancer patients: Report from the National COVID Cohort Collaborative (N3C).
Abstract 1500, Noha Sharafeldin, MBBCh, MSc, PhD | Presented by Ghazi Nsouli, MD

13:00 - 13:10 The future of tele-oncology: Trends and disparities in telehealth and secure message utilization in the COVID-19 era.
Abstract 1506, Elad Neeman, MD | Presented by Hady Ghanem, MD

13:10 - 13:20 Q & A

13:20 - 13:50 Break

13:50 - 14:20 Non-CME non-Best of ASCO Satellite Symposium by Roche
Advances in eTNBC management with cancer immunotherapy | Nagi El Saghir, MD

14:20 - 14:50 Non-CME non-Best of ASCO Satellite Symposium by Lilly
Advancing Progress with CDK4/6i in Metastatic Breast Cancer | Nagi El Saghir, MD

14:50 - 15:20 Non-CME non-Best of ASCO Satellite Symposium by Novartis
Kisqali : Unprecedented Survival, More life Well Lived | Fadi Farhat, MD, MHHM

Friday, July 9th, 2021

15:20 - 16:10 Breast Cancer - Metastatic

Chairpersons: Zahera Fahed, MD - Shaheena Dawoud, MD

Speakers: Nuhad Ibrahim, MD - Hikmat Abdel-Razeq, MD - Nagi El Saghir, MD - Ahmad Awada, MD

- 15:20 - 15:30 Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.
[Abstract 1003, Zhongyu Yuan, Professor](#) | Presented by Nuhad Ibrahim, MD
- 15:30 - 15:40 Dapiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.
[Abstract 1002, Binghe Xu, MD, PhD](#) | Presented by Hikmat Abdel-Razeq, MD
- 15:40 - 15:50 Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).
[Abstract 1005, Anne L Loeser, BS](#) | Presented by Nagi El Saghir, MD
- 15:50 - 16:00 MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors.
[Abstract 3004, Funda Meric-Bernstam, MD \(Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology Section\)](#) | Presented by Ahmad Awada, MD
- 16:00 - 16:10 Q & A

Friday, July 9th, 2021

16:10 - 17:10 Breast Cancer - Local / Regional / Adjuvant / Prevention, Risk Reduction and Hereditary Cancer

Chairpersons: Nagi El Saghir, MD - Hesham El Ghazali, MD - Roger Khater, MD

Speakers: Mark Robson, MD - David Cameron, MD - Nuhad Ibrahim, MD - Sana Al-Sukhun, MD

- 16:10 - 16:20 **Plenary Session Abstract:** OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.
[Abstract LBA1](#), Andrew Tutt, FMedSci, FMedSci, PhD, MBChB | Presented by Mark Robson, MD
- 16:20 - 16:30 Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial.
[Abstract 500](#), Josephine Lopes Cardozo, MD | Presented by David Cameron, MD
- 16:30 - 16:40 Breast Cancer Index (BCI) and Prediction of Benefit from Extended Aromatase Inhibitor (AI) Therapy (tx) in HR+ Breast Cancer: NRG Oncology/NSABP B-42.
[Abstract 501](#), Eleftherios P. Mamounas, MD | Presented by Nuhad Ibrahim, MD
- 16:40 - 16:50 De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.
[Abstract 503](#), Nadia Harbeck, MD | Presented by Sana Al-Sukhun, MD
- 16:50 - 17:00 Nearly half of TP53 variants are misattributed to Li-Fraumeni syndrome: A clinical evaluation of individuals with TP53 variants detected by hereditary cancer panel assays on blood or saliva.
[Abstract 10501](#), Alison Schwartz, MS, CGC | Presented by Mark Robson, MD
- 17:00 - 17:10 Q & A

17:10 - 17:20 Break

Friday, July 9th, 2021

17:20 - 18:20 Genitourinary Cancer - Kidney and Bladder

Chairpersons: Mohamad Bulbul, MD - Hassan Ghazal, MD

Speakers: Toni K. Choueiri, MD - Deborah Mukherji, MD - Joseph Kattan, MD

- 17:20 - 17:30 **Plenary Session Abstract:** Pembrolizumab versus placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase 3 KEYNOTE-564 study.
[Abstract LBA5](#), Toni K. Choueiri, MD | Presented by Toni K. Choueiri, MD
- 17:30 - 17:40 Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
[Abstract 4502](#), Robert J. Motzer, MD | Presented by Toni K. Choueiri, MD
- 17:40 - 17:50 Final analysis of KEYNOTE-426: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC).
[Abstract 4500](#), Brian I. Rini, FASCO, MD | Presented by Toni K. Choueiri, MD
- 17:50 - 18:00 Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.
[Abstract 4520](#), Thomas Powles, MD, PhD, FCRP | Presented by Deborah Mukherji, MD
- 18:00 - 18:10 Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
[Abstract 4509](#), Chung-Han Lee, MD, PhD | Presented by Joseph Kattan, MD
- 18:10 - 18:20 Q & A

Friday, July 9th, 2021

18:20 - 19:00 Genitourinary Cancer - Prostate, Testicular, and Penile

Chairpersons: Albert Hajj, MD - Toufic Eid, MD - Marwan Ghosn, MD

Speakers: Toni K. Choueiri, MD - Ali Shamseddine, MD - Hampig Kourie, MD

18:20 - 18:30 **Plenary Session Abstract:** Phase 3 study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).
[Abstract LBA4](#), Michael J. Morris, MD | Presented by Toni K. Choueiri, MD

18:30 - 18:40 A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
[Abstract 5000](#), Karim Fizazi, MD, PhD | Presented by Ali Shamseddine, MD

18:40 - 18:50 Underdiagnosis of germline genetic prostate cancer: Are genetic testing guidelines an aid or an impediment?.
[Abstract 10504](#), Edward D. Esplin, FACMG, FACP, MD, PhD | Presented by Hampig Kourie, MD

18:50 - 19:00 Q & A

Saturday, July 10th, 2021

09:00 - 09:40 Gynecologic Cancer

Chairperson: Zeina Ayoub, MD

Speakers: Reem Abdallah, MD - Muhieddine Seoud, MD - David Atallah, MD

09:00 - 09:10 **Plenary Session Abstract:** Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase 3 OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).

[Abstract LBA3](#), Linda R. Mileskin, MBBS, MD, FRACP | Presented by Reem Abdallah, MD

09:10 - 09:20 Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).

[Abstract 5501](#), Jacobus Pfisterer, MD, PhD | Presented by Muhieddine Seoud, MD

09:20 - 09:30 Intensive versus minimalist follow-up in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study-NCT00916708).

[Abstract 5506](#), Paolo Zola, MD, PhD | Presented by David Atallah, MD

09:30 - 09:40 Q & A

Saturday, July 10th, 2021

09:40 - 10:10 Pediatric Oncology

Chairperson: Samar Mouwakkit, MD

Speakers: Miguel Abboud, MD - Roula Farah, MD, FAAP

09:40 - 09:50 Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

[Abstract 10005](#), Alanna J. Church, MD | Presented by Miguel Abboud, MD

09:50 - 10:00 Prognostic Impact of CNS-2 status in T-ALL: a report from the Children's Oncology Group.

[Abstract 10003](#), Nathan Gossai, MD | Presented by Roula Farah, MD, FAAP

10:00 - 10:10 Q & A

10:10 - 10:20 Break

Saturday, July 10th, 2021

10:20 - 10:50 Sarcoma

Chairperson: Christina Khater, MD

Speakers: Raya Saab, MD - Haifa Dbouk, MD

10:20 - 10:30 Treatment delays are associated with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial.

[Abstract 11502, Uta Dirksen, Professor](#) | Presented by Raya Saab, MD

10:30 - 10:40 Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.

[Abstract 11516, Chang Gon Kim, MD, PhD](#) | Presented by Haifa Dbouk, MD

10:40 - 10:50 Q & A

Saturday, July 10th, 2021

10:50 - 11:30 Symptoms and Survivorship / Health Services Research and Quality Improvement

Chairperson: Joseph Makdessi, MD

Speakers: Marcel Massoud, MD - Antoine Finianos, MD - Maroun Khoury, MD

10:50 - 11:00 The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial.

[Abstract 12020](#), Deborah Schrag, MD, FASCO, MPH | Presented by Marcel Massoud, MD

11:00 - 11:10 The effects of geriatric assessment on oncologist-patient communication regarding functional status and physical performance in older adults with cancer: A secondary analysis of a 541-subject nationwide URCC NCORP (NCI Community Oncology Research Program) cluster randomized trial.

[Abstract 12010](#), Marielle Jensen-Battaglia, PT, DPT | Presented by Antoine Finianos, MD

11:10 - 11:20 Mobile low-dose computerized tomography (LDCT): Three-year follow up of solution for early diagnosis of lung cancer in under-served populations.

[Abstract 6507](#), Derek Raghavan, MD, PhD, FACP, FASCO | Presented by Maroun Khoury, MD

11:20 - 11:30 Q & A

11:30 Adjourn

SEE YOU in July 2022 at Best of ASCO-22 in-person!